285 related articles for article (PubMed ID: 22351689)
1. RAF265 inhibits the growth of advanced human melanoma tumors.
Su Y; Vilgelm AE; Kelley MC; Hawkins OE; Liu Y; Boyd KL; Kantrow S; Splittgerber RC; Short SP; Sobolik T; Zaja-Milatovic S; Dahlman KB; Amiri KI; Jiang A; Lu P; Shyr Y; Stuart DD; Levy S; Sosman JA; Richmond A
Clin Cancer Res; 2012 Apr; 18(8):2184-98. PubMed ID: 22351689
[TBL] [Abstract][Full Text] [Related]
2. A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.
Izar B; Sharfman W; Hodi FS; Lawrence D; Flaherty KT; Amaravadi R; Kim KB; Puzanov I; Sosman J; Dummer R; Goldinger SM; Lam L; Kakar S; Tang Z; Krieter O; McDermott DF; Atkins MB
Cancer Med; 2017 Aug; 6(8):1904-1914. PubMed ID: 28719152
[TBL] [Abstract][Full Text] [Related]
3. Use of DNA microarray and small animal positron emission tomography in preclinical drug evaluation of RAF265, a novel B-Raf/VEGFR-2 inhibitor.
Tseng JR; Stuart D; Aardalen K; Kaplan A; Aziz N; Hughes NP; Gambhir SS
Neoplasia; 2011 Mar; 13(3):266-75. PubMed ID: 21390189
[TBL] [Abstract][Full Text] [Related]
4. Protein kinase D3 sensitizes RAF inhibitor RAF265 in melanoma cells by preventing reactivation of MAPK signaling.
Chen J; Shen Q; Labow M; Gaither LA
Cancer Res; 2011 Jun; 71(12):4280-91. PubMed ID: 21527556
[TBL] [Abstract][Full Text] [Related]
5.
Sanchez IM; Purwin TJ; Chervoneva I; Erkes DA; Nguyen MQ; Davies MA; Nathanson KL; Kemper K; Peeper DS; Aplin AE
Mol Cancer Ther; 2019 Sep; 18(9):1637-1648. PubMed ID: 31270153
[TBL] [Abstract][Full Text] [Related]
6. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N
Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238
[TBL] [Abstract][Full Text] [Related]
7. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
8. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
[TBL] [Abstract][Full Text] [Related]
9. Preclinical analysis of the anti-tumor and anti-metastatic effects of Raf265 on colon cancer cells and CD26(+) cancer stem cells in colorectal carcinoma.
Chow AK; Cheng NS; Lam CS; Ng L; Wong SK; Wan TM; Man JH; Cheung AH; Yau TC; Poon JT; Law WL; Pang RW
Mol Cancer; 2015 Apr; 14():80. PubMed ID: 25884645
[TBL] [Abstract][Full Text] [Related]
10. Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.
Jalili A; Wagner C; Pashenkov M; Pathria G; Mertz KD; Widlund HR; Lupien M; Brunet JP; Golub TR; Stingl G; Fisher DE; Ramaswamy S; Wagner SN
J Natl Cancer Inst; 2012 Nov; 104(21):1673-9. PubMed ID: 22997239
[TBL] [Abstract][Full Text] [Related]
11. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS
Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686
[TBL] [Abstract][Full Text] [Related]
12. Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cells.
Bertazza L; Barollo S; Radu CM; Cavedon E; Simioni P; Faggian D; Plebani M; Pelizzo MR; Rubin B; Boscaro M; Pezzani R; Mian C
J Cell Mol Med; 2015 Sep; 19(9):2244-52. PubMed ID: 26081844
[TBL] [Abstract][Full Text] [Related]
13. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
14. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.
Del Curatolo A; Conciatori F; Cesta Incani U; Bazzichetto C; Falcone I; Corbo V; D'Agosto S; Eramo A; Sette G; Sperduti I; De Luca T; Marabese M; Shirasawa S; De Maria R; Scarpa A; Broggini M; Del Bufalo D; Cognetti F; Milella M; Ciuffreda L
J Exp Clin Cancer Res; 2018 Jul; 37(1):140. PubMed ID: 29986755
[TBL] [Abstract][Full Text] [Related]
16. Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations.
Ciuffreda L; Del Bufalo D; Desideri M; Di Sanza C; Stoppacciaro A; Ricciardi MR; Chiaretti S; Tavolaro S; Benassi B; Bellacosa A; Foà R; Tafuri A; Cognetti F; Anichini A; Zupi G; Milella M
Neoplasia; 2009 Aug; 11(8):720-31. PubMed ID: 19649202
[TBL] [Abstract][Full Text] [Related]
17. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
[TBL] [Abstract][Full Text] [Related]
18. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
[TBL] [Abstract][Full Text] [Related]
19. Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma.
Sharma A; Madhunapantula SV; Gowda R; Berg A; Neves RI; Robertson GP
Am J Pathol; 2013 Apr; 182(4):1151-62. PubMed ID: 23416158
[TBL] [Abstract][Full Text] [Related]
20.
Tan J; Liu R; Zhu G; Umbricht CB; Xing M
Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15846-15851. PubMed ID: 32561648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
